117 related articles for article (PubMed ID: 8122625)
1. Acquired episodic complete heart block after high-dose chemotherapy with cyclophosphamide and thiotepa.
Ramireddy K; Kane KM; Adhar GC
Am Heart J; 1994 Mar; 127(3):701-4. PubMed ID: 8122625
[No Abstract] [Full Text] [Related]
2. Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation.
Ando M; Yokozawa T; Sawada J; Takaue Y; Togitani K; Kawahigashi N; Narabayashi M; Takeyama K; Tanosaki R; Mineishi S; Kobayashi Y; Watanabe T; Adachi I; Tobinai K
Bone Marrow Transplant; 2000 Jan; 25(2):185-9. PubMed ID: 10673678
[TBL] [Abstract][Full Text] [Related]
3. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
[No Abstract] [Full Text] [Related]
4. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.
Eder JP; Antman K; Elias A; Shea TC; Teicher B; Henner WD; Schryber SM; Holden S; Finberg R; Chritchlow J
J Natl Cancer Inst; 1988 Oct; 80(15):1221-6. PubMed ID: 3138431
[TBL] [Abstract][Full Text] [Related]
5. Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
Mahendra P; Hood IM; Lee MA; Mewar D; Bass G; Flower CD; Wilson CB; Marcus RE
Clin Oncol (R Coll Radiol); 1996; 8(3):198-200. PubMed ID: 8814378
[TBL] [Abstract][Full Text] [Related]
6. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
[TBL] [Abstract][Full Text] [Related]
7. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Przepiorka D; Ippoliti C; Giralt S; van Beisen K; Mehra R; Deisseroth AB; Andersson B; Luna M; Cork A; Lee M
Bone Marrow Transplant; 1994 Sep; 14(3):449-53. PubMed ID: 7994271
[TBL] [Abstract][Full Text] [Related]
8. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
9. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
10. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
11. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
[TBL] [Abstract][Full Text] [Related]
13. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Mileshkin L; Prince HM; Rischin D; Zimet A
Bone Marrow Transplant; 2001 Mar; 27(5):559-63. PubMed ID: 11313694
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
[TBL] [Abstract][Full Text] [Related]
15. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
Wang X; Ren J; Zhang J; Yan Y; Jiang N; Yu J; Di L; Song G; Che L; Jia J; Zhou X; Yang H; Lyerly HK
Clin Transl Oncol; 2016 Jan; 18(1):82-7. PubMed ID: 26266766
[TBL] [Abstract][Full Text] [Related]
17. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
18. High-dose thiotepa alone and in combination regimens with bone marrow support.
Antman K; Eder JP; Elias A; Ayash L; Shea TC; Weissman L; Critchlow J; Schryber SM; Begg C; Teicher BA
Semin Oncol; 1990 Feb; 17(1 Suppl 3):33-8. PubMed ID: 2106166
[TBL] [Abstract][Full Text] [Related]
19. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
20. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer.
Williams SF; Bitran JD; Hoffman PC; Robin E; Fullem L; Beschorner J; Golick J; Golomb HM
Cancer; 1989 Jan; 63(2):238-42. PubMed ID: 2535952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
